<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43525">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881425</url>
  </required_header>
  <id_info>
    <org_study_id>INN005</org_study_id>
    <nct_id>NCT01881425</nct_id>
  </id_info>
  <brief_title>InnFocus MicroShunt Versus Trabeculectomy Study</brief_title>
  <acronym>IMS</acronym>
  <official_title>A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShuntTM Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower
      intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not
      controlled when using maximum tolerated glaucoma medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a prospective, randomized, controlled, multicenter, study. After
      informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
      severity, eye health, and visual acuity. Following successful screening, use of all topical
      glaucoma medications will be stopped for a period of &quot;washout&quot; to establish a qualifying
      medication-free intraocular pressure (IOP) value.

      Clinical follow up will be scheduled over the course of the 24 month study, and examinations
      will be repeated to monitor eye health. At the 1 and 2 year follow up, those patients on
      ocular hypotensive medications will be instructed to washout, and then have the diurnal (IOP
      taken in the morning, mid-day, and afternoon in the same day) IOP evaluation. Annual follow
      up will occur up to 2 years. The primary effectiveness endpoint is a decrease in diurnal IOP
      from baseline compared to the 24 months diurnal IOP following medication washout.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in intraocular pressure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness outcome is the hypotensive medication-free diurnal mean IOP reduction from baseline to 24 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt; 20% decrease in hypotensive medication-free diurnal intraocular pressure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary effectiveness outcome is the proportion of eyes with ≥ 20% decrease in hypotensive medication-free diurnal intraocular pressure from baseline to 24 months post-operative examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">857</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>InnFocus MicroShunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InnFocus MicroShunt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glaucoma surgery to reduce IOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glaucoma Surgery</intervention_name>
    <description>An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a &quot;fornix-based&quot; conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InnFocus MicroShunt</intervention_name>
    <description>An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a &quot;fornix-based&quot; conjunctival incision at the corneoscleral junction.  After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and a 25Ga needle enters through the shallow pocket and enters the AC.  The device is then threaded through the needle track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva.  The conjunctiva is closed in a watertight fashion at the end of the procedure.</description>
    <arm_group_label>InnFocus MicroShunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - POAG on maximum tolerated glaucoma meds - Medicated ≥18mmHg and
        ≤35mmHg - Diurnal unmedicated IOP &gt;21mmHg and &lt;40mmHg Exclusion Criteria: - Previous
        incisional ophthalmic surgery except for cataract surgery - Anticipated need for
        additional ocular surgery during the study - Secondary glaucoma - Any condition that
        prevents the device implantation or trabeculectomy in the superior region of the study eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Palmberg, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Hewitt</last_name>
      <phone>479-442-8653</phone>
      <email>shewitt@voldvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Steven Vold, M.D.</last_name>
      <phone>479-442-8653</phone>
    </contact_backup>
    <investigator>
      <last_name>Steven Vold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Lavin</last_name>
      <phone>203-366-8000</phone>
      <email>dlavin@occeye.com</email>
    </contact>
    <contact_backup>
      <last_name>Robert Noecker, M.D.</last_name>
      <phone>203-366-8000</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert Noecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inter-Mountain Eye Care</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Heinz</last_name>
      <phone>208-841-8624</phone>
      <email>jill.tvcr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adam Reynolds, M.D.</last_name>
      <phone>208-918-4712</phone>
    </contact_backup>
    <investigator>
      <last_name>Adam Reynolds, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eugene and Marilyn Glick Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joni Hoop</last_name>
      <phone>317-274-8975</phone>
      <email>jhoop@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Morgan</last_name>
      <phone>317-274-8975</phone>
      <email>lismorga@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Cantor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russ Schroeder</last_name>
      <phone>913-897-9299</phone>
      <email>RSchroeder@Stileseye.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Stiles, M.D.</last_name>
      <phone>(913) 897-9299</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Stiles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Eye Physicians and Surgeons</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Tzeng</last_name>
      <phone>301-657-5700</phone>
      <email>amtzeng@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kenneth Schwartz, M.D.</last_name>
      <phone>301-657-5700</phone>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Schwartz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Eye Alliance</name>
      <address>
        <city>Alliance</city>
        <state>Ohio</state>
        <zip>44601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lehrer, M.D.</last_name>
      <phone>330-823-1680</phone>
    </contact>
    <contact_backup>
      <last_name>William Patton, OD</last_name>
      <phone>330-823-1680</phone>
    </contact_backup>
    <investigator>
      <last_name>Richard Lehrer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonny Icks</last_name>
      <phone>405-271-6307</phone>
      <email>Sonny-Icks@dmei.org</email>
    </contact>
    <contact_backup>
      <last_name>Mahmoud Khaimi, M.D.</last_name>
      <phone>405-271-6060</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Khaimi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Robert Cizik Eye Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Baker</last_name>
      <phone>713-559-5200</phone>
      <email>LauraBaker@cizikeye.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert Feldman, M.D.</last_name>
      <phone>713-559-5200</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert Feldman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Care</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Cook</last_name>
      <phone>425-454-3937</phone>
      <email>rcook@specialtyeyecarecentre.com</email>
    </contact>
    <contact_backup>
      <last_name>Howard Barnebey, M.D.</last_name>
      <phone>(425) 454-3937</phone>
    </contact_backup>
    <investigator>
      <last_name>Howard Barneby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POAG</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
